Trial reportWorld journal of gastroenterology2007
Chios mastic treatment of patients with active Crohn's disease.
Trial report in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02796339 (A Phase-II Clinical Trial on the Effectiveness of a Nutritional Supplement With Natural Mastiha in Inflammatory Bowel Diseases Patients.), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase-II Clinical Trial on the Effectiveness of a Nutritional Supplement With Natural Mastiha in Inflammatory Bowel Diseases Patients.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis.Redox biology · 2024Pooled it
- On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies.Digestive diseases and sciences · 2009Pooled it
- Chios Mastic in Well-Controlled Hypertension: Findings From the HYPER-MASTIC Randomized Controlled Trial.Pharmacology research & perspectives · 2026Trial
- A First-in-Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers.Clinical pharmacology in drug development · 2020Trial
- Antioxidative Efficacy of aNutrients · 2018Trial
- Article
- Chemical Analysis and Antioxidant Activities of Resin Fractions fromMolecules (Basel, Switzerland) · 2025Article
- Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD.Current gastroenterology reports · 2025Review
- Antioxidant Therapy in Inflammatory Bowel Diseases: How Far Have We Come and How Close Are We?Antioxidants (Basel, Switzerland) · 2024Review
- Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients.Non-coding RNA · 2024Article
- Antioxidant Therapy in Inflammatory Bowel Disease: A Systematic Review and a Meta-Analysis of Randomized Clinical Trials.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Role of Plant-Derived Natural Products in the Management of Inflammatory Bowel Disease-What Is the Clinical Evidence So Far?Life (Basel, Switzerland) · 2023Review
- Chios Mastic Gum: Chemical Profile and Pharmacological Properties in Inflammatory Bowel Disease: From the Past to the Future.International journal of molecular sciences · 2023Review
- A Comprehensive Review of the Role of Complementary and Dietary Medicines in EradicatingIranian journal of pharmaceutical research : IJPR · 2022Review
- Apoptotic, Anti-Inflammatory Activities and Interference with the Glucocorticoid Receptor Signaling of Fractions fromPlants (Basel, Switzerland) · 2022Article
- Entourage effect for phenolic compounds on production and metabolism of mammary epithelial cells.Heliyon · 2022Article
- Overview of Chios Mastic Gum (Nutrients · 2022Review
- Chemical Characterization and Biological Activity of the Mastic Gum Essential Oils ofMolecules (Basel, Switzerland) · 2020Article
- Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis.Molecular nutrition & food research · 2019Article
- Antioxidant and Anti-Inflammatory Properties of Mastiha: A Review of Preclinical and Clinical Studies.Antioxidants (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the effectiveness of mastic administration on the clinical course and plasma inflammatory mediators of patients with active Crohn's disease (CD).
methodsThis pilot study was conducted in patients with established mild to moderately active CD, attending the outpatient clinics of the hospital, and in healthy controls. Ten patients and 8 controls were recruited for a 4-wk treatment with mastic caps (6 caps/d, 0.37 g/cap). All patients successfully completed the protocol. CD Activity Index (CDAI), Nutritional Risk Index (NRI), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemotactic protein-1 (MCP-1), and total antioxidant potential (TAP) were evaluated in the plasma at baseline and at the end of the treatment period. Results were expressed as mean values +/- SE and P < 0.05 was considered to indicate statistical significance.
resultsPatients exhibited significant reduction of CDAI (222.9 +/- 18.7 vs 136.3 +/- 12.3, P = 0.05) as compared to pretreament values. Plasma IL-6 was significantly decreased (21.2 +/- 9.3 pg/mL vs 7.2 +/- 2.8 pg/ mL, P = 0.027), and so did CRP (40.3 +/- 13.1 mg/mL vs 19.7 +/- 5.5, P = 0.028). TAP was significantly increased (0.15 +/- 0.09 vs 0.57 +/- 0.15 mmol/L uric acid, P = 0.036). No patient or control exhibited any kind of side effects.
conclusionThe results suggest that mastic significantly decreased the activity index and the plasma levels of IL-6 and CRP in patients with mildly to moderately active CD. Further double-blind, placebo-controlled studies in a larger number of patients are required to clarify the role of this natural product in the treatment of patients with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.